Vaccine: X最新文献_第10页

Neutralizing antibody response to SARS-CoV-2 variants, as determined by the MSD multiplex assay, following COVID-19 vaccination in cancer patients 在癌症患者接种COVID-19疫苗后，通过MSD多重试验确定对SARS-CoV-2变体的中和抗体反应

IF 2.7 Q3 IMMUNOLOGY

Vaccine: X

Pub Date : 2025-06-19 DOI: 10.1016/j.jvacx.2025.100678

Christopher W. Dukes , Junmin Whiting , Qianxing Mo , Christopher L. Cubitt , Barbara J. Kuter , Brett Leav , Kayoko Kennedy , Julie Rathwell , Shari Pilon-Thomas , Anna R. Giuliano

Background

Immunocompromised populations, especially cancer patients, rely on the effectiveness of the COVID-19 vaccines to protect against severe infection or death, both against the original wild-type (WT) SARS CoV-2 virus and its many variants that have emerged.

Methods

We conducted a study using serum samples from cancer patients who received the original mRNA-1273 COVID-19 vaccine. The Meso Scale Discovery (MSD) multiplex assay was used to assess angiotensin-converting enzyme 2 (ACE2) binding inhibition as a surrogate in this population for neutralization response against the WT SARS-CoV-2 receptor binding domain (RBD) antigen, along with nine of its variants. Confidence intervals were used to compare results between timepoints, and Spearman correlation coefficients were used to compare the results between antigen variants.

Results

A positive correlation was found between the binding inhibition and previously reported neutralizing antibody titers against the WT antigen. All 168 participants showed an increase in binding inhibition following the third vaccine dose against each variant tested, however there was no significant difference in binding inhibition between variants. Positive correlations were also found between binding inhibition and previously reported total antibody titers against the WT antigen at each timepoint. Highest binding inhibitions were to the WT, New York, and Alpha variants, while the lowest were to the Beta and Gamma variants.

Conclusions

Original vaccines against SARS-CoV-2 are immunogenic against the WT virus and many of its variants, even in immunocompromised populations such as cancer patients. Use of the MSD multiplex assay may be an alternative to viral neutralization assays depending on the subject population characteristics.

免疫功能受损人群，特别是癌症患者，依靠COVID-19疫苗的有效性来预防严重感染或死亡，无论是针对原始野生型（WT） SARS CoV-2病毒还是其已出现的许多变体。方法对接种原mRNA-1273 COVID-19疫苗的癌症患者的血清样本进行研究。Meso Scale Discovery （MSD）多重试验用于评估血管紧张素转换酶2 （ACE2）结合抑制作为替代物在该人群中对WT SARS-CoV-2受体结合域（RBD）抗原及其9种变体的中和反应。置信区间用于比较时间点之间的结果，Spearman相关系数用于比较抗原变异之间的结果。结果结合抑制与先前报道的WT抗原中和抗体滴度呈正相关。所有168名参与者在针对每种变体接种第三剂疫苗后都显示出结合抑制增加，但变体之间的结合抑制没有显着差异。在每个时间点，结合抑制与先前报道的针对WT抗原的总抗体滴度之间也发现了正相关。对WT、New York和Alpha变异的结合抑制作用最高，而对Beta和Gamma变异的结合抑制作用最低。结论针对SARS-CoV-2的原始疫苗对WT病毒及其许多变体具有免疫原性，即使在免疫功能低下的人群（如癌症患者）中也是如此。根据受试者群体特征，使用MSD多重测定法可以替代病毒中和测定法。

{"title":"Neutralizing antibody response to SARS-CoV-2 variants, as determined by the MSD multiplex assay, following COVID-19 vaccination in cancer patients","authors":"Christopher W. Dukes , Junmin Whiting , Qianxing Mo , Christopher L. Cubitt , Barbara J. Kuter , Brett Leav , Kayoko Kennedy , Julie Rathwell , Shari Pilon-Thomas , Anna R. Giuliano","doi":"10.1016/j.jvacx.2025.100678","DOIUrl":"10.1016/j.jvacx.2025.100678","url":null,"abstract":"<div><h3>Background</h3><div>Immunocompromised populations, especially cancer patients, rely on the effectiveness of the COVID-19 vaccines to protect against severe infection or death, both against the original wild-type (WT) SARS CoV-2 virus and its many variants that have emerged.</div></div><div><h3>Methods</h3><div>We conducted a study using serum samples from cancer patients who received the original mRNA-1273 COVID-19 vaccine. The Meso Scale Discovery (MSD) multiplex assay was used to assess angiotensin-converting enzyme 2 (ACE2) binding inhibition as a surrogate in this population for neutralization response against the WT SARS-CoV-2 receptor binding domain (RBD) antigen, along with nine of its variants. Confidence intervals were used to compare results between timepoints, and Spearman correlation coefficients were used to compare the results between antigen variants.</div></div><div><h3>Results</h3><div>A positive correlation was found between the binding inhibition and previously reported neutralizing antibody titers against the WT antigen. All 168 participants showed an increase in binding inhibition following the third vaccine dose against each variant tested, however there was no significant difference in binding inhibition between variants. Positive correlations were also found between binding inhibition and previously reported total antibody titers against the WT antigen at each timepoint. Highest binding inhibitions were to the WT, New York, and Alpha variants, while the lowest were to the Beta and Gamma variants.</div></div><div><h3>Conclusions</h3><div>Original vaccines against SARS-CoV-2 are immunogenic against the WT virus and many of its variants, even in immunocompromised populations such as cancer patients. Use of the MSD multiplex assay may be an alternative to viral neutralization assays depending on the subject population characteristics.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"25 ","pages":"Article 100678"},"PeriodicalIF":2.7,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144322062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Programming immunogenicity of dengue EDIII vaccine antigens using engineered outer membrane vesicles (OMVs) 利用工程外膜囊（OMVs）对登革ⅱ型疫苗抗原的免疫原性进行编程

IF 2.7 Q3 IMMUNOLOGY

Vaccine: X

Pub Date : 2025-06-19 DOI: 10.1016/j.jvacx.2025.100679

Srinivas Duvvada , Farhan Ahmed , Rafiq Ahmad Khan , Shaikh Matin Rahim , Saima Naz , Aradhana Mariam Philips , David Putnam , Avery August , Nooruddin Khan

Dengue is a mosquito-borne viral infection and is more prevalent in the world with no therapeutics and suboptimal vaccine (Dengvaxia) performance against all four serotypes of the dengue virus. Hence, there is an urgent requirement for a non-infectious and non-replicative vaccine candidate that can elicit a balanced and serotype-specific immune response. In this study, we have engineered bacterial outer membrane vesicles (rOMVs) that display EDIII antigens (EDIII rOMVs). The current formulation modulates the expression of costimulatory molecules on antigen-presenting cells (APCs) as well as enhances the uptake and presentation. Subsequently, the EDIII rOMVs elicited a strong antigen-specific polyfunctional response from CD4+ and CD8 + T cells. The robust antibody response was facilitated by a germinal center reaction characterized by high T follicular helper (Tfh) and B cell response levels in the mice that received EDIII rOMVs. Notably, the produced antibodies demonstrated the ability to neutralize all four dengue virus serotypes in an in vitro infection model, indicating its potential role in protective immunity.

登革热是一种蚊子传播的病毒感染，在世界上更为普遍，目前尚无治疗方法，针对所有四种血清型登革热病毒的登卡夏疫苗（Dengvaxia）表现不佳。因此，迫切需要一种能够引起平衡和血清型特异性免疫反应的非传染性和非复制性候选疫苗。在这项研究中，我们设计了显示EDIII抗原的细菌外膜囊泡（rOMVs）（EDIII rOMVs）。目前的配方调节共刺激分子在抗原呈递细胞（APCs）上的表达，并增强抗原的摄取和呈递。随后，EDIII romv在CD4+和CD8 + T细胞中引发了强烈的抗原特异性多功能反应。在接受EDIII rOMVs的小鼠中，以高T滤泡辅助细胞（Tfh）和B细胞应答水平为特征的生发中心反应促进了稳健的抗体应答。值得注意的是，在体外感染模型中，所产生的抗体显示出能够中和所有四种登革热病毒血清型，表明其在保护性免疫中的潜在作用。

{"title":"Programming immunogenicity of dengue EDIII vaccine antigens using engineered outer membrane vesicles (OMVs)","authors":"Srinivas Duvvada , Farhan Ahmed , Rafiq Ahmad Khan , Shaikh Matin Rahim , Saima Naz , Aradhana Mariam Philips , David Putnam , Avery August , Nooruddin Khan","doi":"10.1016/j.jvacx.2025.100679","DOIUrl":"10.1016/j.jvacx.2025.100679","url":null,"abstract":"<div><div>Dengue is a mosquito-borne viral infection and is more prevalent in the world with no therapeutics and suboptimal vaccine (Dengvaxia) performance against all four serotypes of the dengue virus. Hence, there is an urgent requirement for a non-infectious and non-replicative vaccine candidate that can elicit a balanced and serotype-specific immune response. In this study, we have engineered bacterial outer membrane vesicles (rOMVs) that display EDIII antigens (EDIII rOMVs). The current formulation modulates the expression of costimulatory molecules on antigen-presenting cells (APCs) as well as enhances the uptake and presentation. Subsequently, the EDIII rOMVs elicited a strong antigen-specific polyfunctional response from CD4+ and CD8 + T cells. The robust antibody response was facilitated by a germinal center reaction characterized by high T follicular helper (Tfh) and B cell response levels in the mice that received EDIII rOMVs. Notably, the produced antibodies demonstrated the ability to neutralize all four dengue virus serotypes in an in vitro infection model, indicating its potential role in protective immunity.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"25 ","pages":"Article 100679"},"PeriodicalIF":2.7,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144338339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of public funding for rotavirus vaccines on pediatric emergencies and healthcare workload in a tertiary care hospital 轮状病毒疫苗公共资金对儿科急诊和三级保健医院保健工作量的影响

IF 2.7 Q3 IMMUNOLOGY

Vaccine: X

Pub Date : 2025-06-18 DOI: 10.1016/j.jvacx.2025.100677

Madoka Hoshide , Reiji Fukano , Kazumasa Takahashi , Yasuo Suzuki , Eitaro Suzuki , Komei Shirabe , Seigo Korematsu , M.H. Mahbub , Tsuyoshi Tanabe , Shunji Hasegawa

Background

Optional rotavirus vaccination was initiated in Japan in November 2011. From January 2014, Ube City initiated a subsidized vaccination program, until this ultimately became a nationwide practice in October 2020. We evaluated the impact of this municipal funding program on pediatric emergencies in Yamaguchi University Hospital, an advanced medical care institute.

Methods

We compared the trends in hospitalization and after-hour emergency outpatient visits attributable to rotavirus gastroenteritis at the pediatric department of this institute from 2010 to 2020, encompassing periods both before and after the implementation of municipal funding. We further compared the incidence of rotavirus infection with that in neighboring areas, where such a subsidy was not provided.

Results

Following the introduction of public subsidies, significant reductions were observed in the number of hospitalizations for rotavirus gastroenteritis (p = 0.0097) and after-hours visits at our department (p = 0.013). Vaccination rates per year during the subsidization (2014–2020) ranged from 72.1 to 95.1 %. The number of sentinel reports of rotavirus infection in Ube Health Center area was much lower than non-subsidized adjacent areas (Shimonoseki [p = 0.0070] and Yamaguchi [p < 0.0001]).

Conclusions

This municipal funding led to a change in rotavirus-related hospitalization and emergency visits to our hospital, which contributed to an appreciable reduction in medical expenses and physician workload.

日本于2011年11月启动了轮状病毒可选疫苗接种。从2014年1月起，宇部市启动了一项补贴疫苗接种计划，直到最终在2020年10月成为全国范围内的做法。我们评估了这项市政资助计划对山口大学医院儿科急诊的影响，山口大学医院是一家先进的医疗机构。方法比较2010 - 2020年该所儿科轮状病毒胃肠炎住院率和小时后急诊门诊率的变化趋势，包括实施市级资助前后。我们进一步将轮状病毒感染的发病率与没有提供这种补贴的邻近地区进行了比较。结果引入公共补贴后，轮状病毒胃肠炎住院次数（p = 0.0097）和我科非工作时间就诊次数（p = 0.013）显著减少。补贴期间（2014-2020年）每年的疫苗接种率为72.1%至95.1%。宇部保健中心地区轮状病毒感染的哨点报告数量远低于未补贴的邻近地区(下关[p = 0.0070]和山口[p <；0.0001])。结论市政资金的投入使我院轮状病毒相关住院和急诊人数发生了变化，大大减少了医疗费用和医生工作量。

{"title":"Impact of public funding for rotavirus vaccines on pediatric emergencies and healthcare workload in a tertiary care hospital","authors":"Madoka Hoshide , Reiji Fukano , Kazumasa Takahashi , Yasuo Suzuki , Eitaro Suzuki , Komei Shirabe , Seigo Korematsu , M.H. Mahbub , Tsuyoshi Tanabe , Shunji Hasegawa","doi":"10.1016/j.jvacx.2025.100677","DOIUrl":"10.1016/j.jvacx.2025.100677","url":null,"abstract":"<div><h3>Background</h3><div>Optional rotavirus vaccination was initiated in Japan in November 2011. From January 2014, Ube City initiated a subsidized vaccination program, until this ultimately became a nationwide practice in October 2020. We evaluated the impact of this municipal funding program on pediatric emergencies in Yamaguchi University Hospital, an advanced medical care institute.</div></div><div><h3>Methods</h3><div>We compared the trends in hospitalization and after-hour emergency outpatient visits attributable to rotavirus gastroenteritis at the pediatric department of this institute from 2010 to 2020, encompassing periods both before and after the implementation of municipal funding. We further compared the incidence of rotavirus infection with that in neighboring areas, where such a subsidy was not provided.</div></div><div><h3>Results</h3><div>Following the introduction of public subsidies, significant reductions were observed in the number of hospitalizations for rotavirus gastroenteritis (<em>p</em> = 0.0097) and after-hours visits at our department (<em>p</em> = 0.013). Vaccination rates per year during the subsidization (2014–2020) ranged from 72.1 to 95.1 %. The number of sentinel reports of rotavirus infection in Ube Health Center area was much lower than non-subsidized adjacent areas (Shimonoseki [<em>p</em> = 0.0070] and Yamaguchi [<em>p</em> < 0.0001]).</div></div><div><h3>Conclusions</h3><div>This municipal funding led to a change in rotavirus-related hospitalization and emergency visits to our hospital, which contributed to an appreciable reduction in medical expenses and physician workload.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"25 ","pages":"Article 100677"},"PeriodicalIF":2.7,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144522182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rhamnose polysaccharide-decorated outer membrane vesicles as a vaccine candidate targeting Group A Streptococcus from Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis 鼠李糖多糖修饰的外膜囊泡作为一种针对化脓性链球菌和乳糖不良链球菌a群链球菌的候选疫苗。equisimilis

IF 2.7 Q3 IMMUNOLOGY

Vaccine: X

Pub Date : 2025-06-11 DOI: 10.1016/j.jvacx.2025.100676

Sowmya Ajay Castro , Sarah Thomson , Helen Alexandra Shaw , Azul Zorzoli , Benjamin H. Meyer , Mark Reglinski , Mark McNeil , Helge C. Dorfmueller

Group A Streptococcus (Strep A) cause a wide range of human-exclusive infections, annually killing more than 500,000 people. Antibiotic resistance incidence of invasive Strep A tripled in the past decade and emphasises the need to develop a universal Strep A vaccine. In this study, we developed recombinant rhamnose polysaccharides (RhaPS), a validated universal Strep A vaccine candidate, presented on E. coli outer membrane vesicles (OMVs). We investigated OMV-RhaPS for their immunogenicity in the mouse and rabbit models. Through flow cytometry, ELISA, and immunofluorescence microscopy, we demonstrated that RhaPS-specific antibodies recognise Strep A strains via the Group A Carbohydrate (GAC) in S. pyogenes and the newly emerged S. dysgalactiae subsp. equisimilis. Elevated IL-17A levels from RhaPS-OMV-immunised splenocytes were detected when re-stimulated with the immunogen RhaPS-OMV. We report the efficacy and potency of recombinant produced RhaPS triggering antibodies that recognise Strep A bacteria and facilitate monocyte dependent opsonophagocytosis of several Strep A serotypes.

A组链球菌（Strep A）引起广泛的人类专属感染，每年造成50多万人死亡。在过去十年中，侵袭性甲型链球菌的抗生素耐药性发生率增加了两倍，这强调了开发一种通用甲型链球菌疫苗的必要性。在这项研究中，我们开发了重组鼠李糖多糖（RhaPS），这是一种经过验证的通用甲型链球菌候选疫苗，用于大肠杆菌外膜囊泡（OMVs）。我们研究了OMV-RhaPS在小鼠和家兔模型中的免疫原性。通过流式细胞术、ELISA和免疫荧光显微镜，我们证明了rhaps特异性抗体通过化脓性链球菌和新出现的dysgalactiae亚型中的A族碳水化合物（GAC）识别链球菌A菌株。equisimilis。用免疫原RhaPS-OMV再次刺激后，检测到经RhaPS-OMV免疫的脾细胞IL-17A水平升高。我们报道了重组生产的RhaPS的功效和效力，这些RhaPS触发了识别链球菌A细菌的抗体，并促进了几种链球菌A血清型的单核细胞依赖性调理吞噬。

{"title":"Rhamnose polysaccharide-decorated outer membrane vesicles as a vaccine candidate targeting Group A Streptococcus from Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis","authors":"Sowmya Ajay Castro , Sarah Thomson , Helen Alexandra Shaw , Azul Zorzoli , Benjamin H. Meyer , Mark Reglinski , Mark McNeil , Helge C. Dorfmueller","doi":"10.1016/j.jvacx.2025.100676","DOIUrl":"10.1016/j.jvacx.2025.100676","url":null,"abstract":"<div><div>Group A Streptococcus (Strep A) cause a wide range of human-exclusive infections, annually killing more than 500,000 people. Antibiotic resistance incidence of invasive Strep A tripled in the past decade and emphasises the need to develop a universal Strep A vaccine. In this study, we developed recombinant rhamnose polysaccharides (RhaPS), a validated universal Strep A vaccine candidate, presented on <em>E. coli</em> outer membrane vesicles (OMVs). We investigated OMV-RhaPS for their immunogenicity in the mouse and rabbit models. Through flow cytometry, ELISA, and immunofluorescence microscopy, we demonstrated that RhaPS-specific antibodies recognise Strep A strains via the Group A Carbohydrate (GAC) in <em>S. pyogenes</em> and the newly emerged <em>S. dysgalactiae</em> subsp. <em>equisimilis</em>. Elevated IL-17A levels from RhaPS-OMV-immunised splenocytes were detected when re-stimulated with the immunogen RhaPS-OMV. We report the efficacy and potency of recombinant produced RhaPS triggering antibodies that recognise Strep A bacteria and facilitate monocyte dependent opsonophagocytosis of several Strep A serotypes.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"25 ","pages":"Article 100676"},"PeriodicalIF":2.7,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144279269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Parental approval and perceptions of the HPV vaccine in indigenous boys from a rural community after their inclusion in the immunization program in Peru 秘鲁农村社区土著男孩被纳入免疫规划后，父母对HPV疫苗的认可和看法

IF 2.7 Q3 IMMUNOLOGY

Vaccine: X

Pub Date : 2025-06-09 DOI: 10.1016/j.jvacx.2025.100674

Yuliana Mercedes De La Cruz-Ramirez , Augusto Felix Olaza-Maguiña , Santiago Angel Cortez-Orellana

The Peruvian health authorities approved HPV vaccination in boys from 9 to 13 years old in April 2023. The main objective of this research was to determine the percentage of parental approval and perceptions of the HPV vaccine in indigenous boys from a Peruvian rural community. A cross-sectional study was developed with 126 parents from Tumpa community, to whom the staff of the health center of said community requested the respective vaccination authorization between April and December 2023. A questionnaire was administered by the authors of this research between January and July 2024, prior informed consent declaration. It was evidenced that 56.3 % of parents rejected the HPV vaccine. The protection it provides against various types of cancer and the fear of future diseases in their boys due to said vaccine were the main positive and negative perceptions, respectively. With the exception of marital status and work status, a statistically significant association was found between the parental approval of the HPV vaccine and the sociodemographic characteristics and perceptions of parents. It was concluded that the percentage of parental approval of the HPV vaccine in indigenous boys was only 43.7 %, so educational activities that address the identified characteristics and perceptions should be promoted.

秘鲁卫生当局于2023年4月批准对9至13岁男孩接种人乳头瘤病毒疫苗。本研究的主要目的是确定秘鲁农村社区土著男孩中父母对HPV疫苗的认可和看法的百分比。对来自Tumpa社区的126名家长进行了一项横断面研究，该社区卫生中心的工作人员在2023年4月至12月期间向他们申请了相应的疫苗接种授权。本研究的作者在2024年1月至7月期间进行了问卷调查，事先知情同意声明。有证据表明，56.3%的家长拒绝接种HPV疫苗。疫苗提供的预防各种癌症的保护和对男孩将来因该疫苗而患病的恐惧分别是主要的积极和消极看法。除婚姻状况和工作状况外，父母对HPV疫苗的认可与父母的社会人口学特征和看法之间存在统计学上显著的关联。结论是，土著男孩中父母批准HPV疫苗的比例仅为43.7%，因此应促进针对已确定的特征和观念的教育活动。

{"title":"Parental approval and perceptions of the HPV vaccine in indigenous boys from a rural community after their inclusion in the immunization program in Peru","authors":"Yuliana Mercedes De La Cruz-Ramirez , Augusto Felix Olaza-Maguiña , Santiago Angel Cortez-Orellana","doi":"10.1016/j.jvacx.2025.100674","DOIUrl":"10.1016/j.jvacx.2025.100674","url":null,"abstract":"<div><div>The Peruvian health authorities approved HPV vaccination in boys from 9 to 13 years old in April 2023. The main objective of this research was to determine the percentage of parental approval and perceptions of the HPV vaccine in indigenous boys from a Peruvian rural community. A cross-sectional study was developed with 126 parents from Tumpa community, to whom the staff of the health center of said community requested the respective vaccination authorization between April and December 2023. A questionnaire was administered by the authors of this research between January and July 2024, prior informed consent declaration. It was evidenced that 56.3 % of parents rejected the HPV vaccine. The protection it provides against various types of cancer and the fear of future diseases in their boys due to said vaccine were the main positive and negative perceptions, respectively. With the exception of marital status and work status, a statistically significant association was found between the parental approval of the HPV vaccine and the sociodemographic characteristics and perceptions of parents. It was concluded that the percentage of parental approval of the HPV vaccine in indigenous boys was only 43.7 %, so educational activities that address the identified characteristics and perceptions should be promoted.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"25 ","pages":"Article 100674"},"PeriodicalIF":2.7,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144262311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Measles second dose vaccination coverage and associated factors in Ethiopia: A systematic review and meta-analysis 埃塞俄比亚麻疹第二剂疫苗接种覆盖率及相关因素：系统回顾和荟萃分析

IF 2.7 Q3 IMMUNOLOGY

Vaccine: X

Pub Date : 2025-06-07 DOI: 10.1016/j.jvacx.2025.100675

Aklilu Alemayehu , Sisay Tefera

Background

Measles-containing vaccine second dose (MCV2) is an important intervention employed to eliminate measles that mainly affect children. Although there are few original studies, comprehensive data that can guide evidence-based decision making to mitigate measles in Ethiopia is limited. Thus, this systematic review and meta-analysis aimed to synthesize evidence to fill this gap.

Methods

Online searching, selection, data extraction, and quality assessment were conducted by two authors. Data were extracted using Microsoft Excel Spreadsheet Version 19.0 and analyzed using STATA Version 17.0. Pooled estimates were determined by a random-effect meta-analysis. Sub-group analysis was conducted to account for sources of heterogeneity. Results are presented in narration, tables, and figures.

Results

Eight cross-sectional studies involving 4416 participants from four regions of Ethiopia were included in this SRMA. The pooled coverage of MCV2 vaccination in Ethiopia was 50.5 % [95 % confidence interval (CI): 39.0–61.9]. Maternal education [odds ratio (OR) = 2.14 95 % CI: 1.22–3.05)], child delivery in a health facility (OR = 2.16 95 % CI: 1.30–3.02), having knowledge about child immunization (OR = 2.24 95 % CI: 1.61–2.87), favorable attitude towards child immunization (OR = 4.30 95 % CI: 2.63–5.97), having awareness about MCV2 vaccination (OR = 2.04 95 % CI: 1.48–2.59), having postnatal follow-up (OR = 2.52 95 % CI: 1.39–3.65), and utilization of other vaccines and supplements (OR = 4.17 95 % CI: 2.05–6.28) were factors associated with MCV2 vaccination coverage.

Conclusion

The coverage of MCV2 vaccination in Ethiopia is sub-optimal. The identified factors should be targeted to improve MCV2 vaccination coverage, and hence strengthen measles mitigation.

背景含麻疹疫苗第二剂（MCV2）是消除主要影响儿童的麻疹的重要干预措施。尽管原始研究很少，但能够指导以证据为基础的决策以减轻埃塞俄比亚麻疹的综合数据有限。因此，本系统综述和荟萃分析旨在综合证据来填补这一空白。方法由两位作者进行在线检索、筛选、资料提取和质量评价。使用Microsoft Excel Version 19.0进行数据提取，使用STATA Version 17.0进行数据分析。汇总估计由随机效应荟萃分析确定。进行亚组分析以解释异质性的来源。结果以叙述、表格和图表的形式呈现。结果8项横断面研究纳入了来自埃塞俄比亚4个地区的4416名参与者。埃塞俄比亚MCV2疫苗接种的总覆盖率为50.5%[95%置信区间（CI）： 39.0-61.9]。产妇教育(优势比(或)= 2.14 95%置信区间:1.22 - -3.05)],孩子在卫生设施交付(或= 2.16 95%置信区间:1.30—-3.02),有知识孩子免疫(或= 2.24 95%置信区间:1.61—-2.87),良好的态度儿童免疫接种(OR = 4.30 95%可信区间:2.63 - -5.97),在对MCV2接种疫苗(或= 2.04 95%置信区间:1.48—-2.59),在产后随访(或= 2.52 95%置信区间:1.39—-3.65),利用其他疫苗和补充剂(OR = 4.17 95% CI:2.05-6.28)是与MCV2疫苗接种覆盖率相关的因素。结论埃塞俄比亚MCV2疫苗接种覆盖率不理想。应以确定的因素为目标，提高MCV2疫苗接种覆盖率，从而加强麻疹缓解。

{"title":"Measles second dose vaccination coverage and associated factors in Ethiopia: A systematic review and meta-analysis","authors":"Aklilu Alemayehu , Sisay Tefera","doi":"10.1016/j.jvacx.2025.100675","DOIUrl":"10.1016/j.jvacx.2025.100675","url":null,"abstract":"<div><h3>Background</h3><div>Measles-containing vaccine second dose (MCV2) is an important intervention employed to eliminate measles that mainly affect children. Although there are few original studies, comprehensive data that can guide evidence-based decision making to mitigate measles in Ethiopia is limited. Thus, this systematic review and meta-analysis aimed to synthesize evidence to fill this gap.</div></div><div><h3>Methods</h3><div>Online searching, selection, data extraction, and quality assessment were conducted by two authors. Data were extracted using Microsoft Excel Spreadsheet Version 19.0 and analyzed using STATA Version 17.0. Pooled estimates were determined by a random-effect meta-analysis. Sub-group analysis was conducted to account for sources of heterogeneity. Results are presented in narration, tables, and figures.</div></div><div><h3>Results</h3><div>Eight cross-sectional studies involving 4416 participants from four regions of Ethiopia were included in this SRMA. The pooled coverage of MCV2 vaccination in Ethiopia was 50.5 % [95 % confidence interval (CI): 39.0–61.9]. Maternal education [odds ratio (OR) = 2.14 95 % CI: 1.22–3.05)], child delivery in a health facility (OR = 2.16 95 % CI: 1.30–3.02), having knowledge about child immunization (OR = 2.24 95 % CI: 1.61–2.87), favorable attitude towards child immunization (OR = 4.30 95 % CI: 2.63–5.97), having awareness about MCV2 vaccination (OR = 2.04 95 % CI: 1.48–2.59), having postnatal follow-up (OR = 2.52 95 % CI: 1.39–3.65), and utilization of other vaccines and supplements (OR = 4.17 95 % CI: 2.05–6.28) were factors associated with MCV2 vaccination coverage.</div></div><div><h3>Conclusion</h3><div>The coverage of MCV2 vaccination in Ethiopia is sub-optimal. The identified factors should be targeted to improve MCV2 vaccination coverage, and hence strengthen measles mitigation.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"25 ","pages":"Article 100675"},"PeriodicalIF":2.7,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144255342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring vaccination literacy and vaccine hesitancy in seven European countries: results from the HLS19 population survey 探索七个欧洲国家的疫苗接种素养和疫苗犹豫：来自HLS19人口调查的结果

IF 2.7 Q3 IMMUNOLOGY

Vaccine: X

Pub Date : 2025-06-02 DOI: 10.1016/j.jvacx.2025.100671

Bakary Cissé , Aldo Rosano , Robert Griebler , Brigid Unim , Chiara Lorini , Guglielmo Bonaccorsi , Mitja Vrdelja , Sophie Fégueux , Julien Mancini , Stephan Van den Broucke , For the HLS19 Consortium

Improving Vaccine Literacy (VAC-HL) is a promise strategy to reduce vaccine hesitancy (VH). VAC-HL refers to the individual ability to access, understand, critically appraise, and apply vaccination-related information to make informed decisions about vaccinations for themselves or for others to be vaccinated. This study explores the pathways through which VAC-HL impacts VH.

The analysis was based on data from seven countries of the WHO European Region which implemented the Health Literacy Survey 2019–2021 (HLS₁₉). VH was measured by a proxy for self-reported vaccination behaviour of respondents or their family members (e.g., children) over the past five years, while VAC-HL was assessed using four items stemming from the 47-item health literacy questionnaire used in HLS₁₉ (HLS₁₉-Q47). A multilevel structural equation model was applied to examine the mediation role of vaccination attitudes - confidence, complacency, conspiracy beliefs - in the relationship between VAC-HL and VH, controlling for socio-economic confounding factors.

The results showed that individuals with high levels of VAC-HL are less likely to be unvaccinated (OR = 0.67, 95 % CI = 0.64–0.70). The inclusion of mediation variables in the model reduced slightly the association but it remained statistically significant (OR = 0.82, 95 % CI = 0.80–0.83). About 27.10 % of the association between VAC-HL and VH was mediated by confidence, 6.58 % by complacency and 17.30 % by conspiracy.

Enhancing VAC-HL might have a positive effect on restoring confidence in vaccination and reducing complacency and conspiracy beliefs, which are essential for improving vaccination uptake.

提高疫苗素养（VAC-HL）是减少疫苗犹豫（VH）的一种有希望的策略。VAC-HL是指个人获取、理解、批判性评估和应用疫苗接种相关信息的能力，以便为自己或他人接种疫苗做出明智的疫苗接种决定。本研究探讨了vaca - hl影响VH的途径。该分析基于世卫组织欧洲区域实施2019-2021年健康素养调查（HLS19）的七个国家的数据。VH是通过受访者或其家庭成员（如儿童）在过去五年中自我报告的疫苗接种行为来衡量的，而vacl - hl是通过来自HLS19 （HLS19- q47）中47项健康素养问卷的4项来评估的。在控制社会经济混杂因素的情况下，采用多层次结构方程模型来检验疫苗接种态度（信心、自满、阴谋信念）在VAC-HL和VH之间关系中的中介作用。结果显示，vachl水平高的个体不太可能未接种疫苗（OR = 0.67, 95% CI = 0.64-0.70）。在模型中加入中介变量略微降低了相关性，但仍然具有统计学意义（OR = 0.82, 95% CI = 0.80-0.83）。VAC-HL与VH的相关性约27.10%由自信介导，6.58%由自满介导，17.30%由阴谋介导。加强vacl - hl可能对恢复对疫苗接种的信心和减少自满情绪和阴谋信念产生积极影响，这对于提高疫苗接种率至关重要。

{"title":"Exploring vaccination literacy and vaccine hesitancy in seven European countries: results from the HLS19 population survey","authors":"Bakary Cissé , Aldo Rosano , Robert Griebler , Brigid Unim , Chiara Lorini , Guglielmo Bonaccorsi , Mitja Vrdelja , Sophie Fégueux , Julien Mancini , Stephan Van den Broucke , For the HLS19 Consortium","doi":"10.1016/j.jvacx.2025.100671","DOIUrl":"10.1016/j.jvacx.2025.100671","url":null,"abstract":"<div><div>Improving Vaccine Literacy (VAC-HL) is a promise strategy to reduce vaccine hesitancy (VH). VAC-HL refers to the individual ability to access, understand, critically appraise, and apply vaccination-related information to make informed decisions about vaccinations for themselves or for others to be vaccinated. This study explores the pathways through which VAC-HL impacts VH.</div><div>The analysis was based on data from seven countries of the WHO European Region which implemented the Health Literacy Survey 2019–2021 (HLS<sub>19</sub>). VH was measured by a proxy for self-reported vaccination behaviour of respondents or their family members (e.g., children) over the past five years, while VAC-HL was assessed using four items stemming from the 47-item health literacy questionnaire used in HLS<sub>19</sub> (HLS<sub>19</sub>-Q47). A multilevel structural equation model was applied to examine the mediation role of vaccination attitudes - confidence, complacency, conspiracy beliefs - in the relationship between VAC-HL and VH, controlling for socio-economic confounding factors.</div><div>The results showed that individuals with high levels of VAC-HL are less likely to be unvaccinated (OR = 0.67, 95 % CI = 0.64–0.70). The inclusion of mediation variables in the model reduced slightly the association but it remained statistically significant (OR = 0.82, 95 % CI = 0.80–0.83). About 27.10 % of the association between VAC-HL and VH was mediated by confidence, 6.58 % by complacency and 17.30 % by conspiracy.</div><div>Enhancing VAC-HL might have a positive effect on restoring confidence in vaccination and reducing complacency and conspiracy beliefs, which are essential for improving vaccination uptake.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"25 ","pages":"Article 100671"},"PeriodicalIF":2.7,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144231717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Evaluation of a novel liquid stabilised peste des petits ruminants vaccine: Safety and immunogenic efficacy in sheep and goats in the field in Jordan” [Vaccine X 15 (2023) 100363] “评价一种新型液体稳定小反刍害虫疫苗：约旦田间绵羊和山羊的安全性和免疫原性效力”的勘误表[疫苗X 15 (2023) 100363]

IF 2.7 Q3 IMMUNOLOGY

Vaccine: X

Pub Date : 2025-06-01 DOI: 10.1016/j.jvacx.2025.100653

Fraser Crofts , Ahmad Al-Majali , David Gerring , Simon Gubbins , Matthew Tully , Hayley Hicks , Dana Campbell , Jeremy Salt , Steve Wilson , Lizzie Chesang , Kristin Stuke , Claudia Cordel , Satya Parida , Carrie Batten

引用次数: 0

Corrigendum to “Immunization of children with inflammatory bowel disease against SARS-CoV-19 infection: A prospective single centre cohort study” [Vaccine:X 15 (2023) 100374] “炎性肠病儿童预防SARS-CoV-19感染的免疫接种：一项前瞻性单中心队列研究”的勘误表[疫苗：x15 (2023) 100374]

IF 2.7 Q3 IMMUNOLOGY

Vaccine: X

Pub Date : 2025-06-01 DOI: 10.1016/j.jvacx.2025.100652

Dóra Dohos , Anna Karoliny , Eszter Gombos , Éva Rimanóczy , Katalin E. Müller

引用次数: 0

Corrigendum to “Vaccination, information and parental confidence in the digital age in England” [Vaccine: X 14 (2023) 100345] “英格兰数字时代的疫苗接种、信息和父母信心”的勘误表[疫苗：X 14 (2023) 100345]

IF 2.7 Q3 IMMUNOLOGY

Vaccine: X

Pub Date : 2025-06-01 DOI: 10.1016/j.jvacx.2025.100651

H. Campbell , P. Paterson , L. Letley , V. Saliba , S. Mounier-Jack , J. Yarwood

引用次数: 0